Food Allergies

• FARE (Food Allergy Research & Education) Resources
• Common Allergens
• Understanding Food Labels
• It’s a Disease, Not a Diet: A documentary about life with food allergies
• Recognize and Respond to Anaphylaxis
• Children With Food Allergies
• Living with Food Allergies: Preparing for College
• Omalizumab for the Treatment of Multiple Food Allergies
• Omalizumab Prescribing Information
• Peanut Oral Immunotherapy Prescribing Information
• Clinical Burden of Food Allergies: Insights from the FARE Patient Registry
• Mental Health Burden of Food Allergies: Insights from Patients and Their Caregivers from FARE Patient Registry
• Food Allergies: National Institute of Allergy and Infectious Diseases
• Food Allergy Information from the American College of Allergy, Asthma & Immunology
• Kids With Food Allergies
• FARE powered by Sifter Shopping Tool for Food Allergy Needs
• Food allergy, mechanisms, diagnosis and treatment: Innovation through a multi-targeted approach
• FDA: Food Allergies
• What you need to know about the new guidelines for the diagnosis and management of food allergy in the U.S.
• Managing food allergy: GA2LEN guideline 2022
• Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary for Patients, Families, and Caregivers
• AR101 Oral Immunotherapy for Peanut Allergy

Asthma

• Dupilumab Prescribing Information
• Tezepelumab Prescribing Information
• Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma
• Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines – recommendations on the use of biologicals in severe asthma
• Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma
• Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma
• 2022 GINA Pocket Guide for Asthma Management and Prevention (for Adults and Children Older Than 5 Years)
• 2022 GINA Main Report: Global Strategy for Asthma Management and Prevention
• American Lung Association: Severe Asthma
• Biological treatments for severe asthma: A major advance in asthma care
• Advances and recent developments in asthma in 2020
• Asthma biologics: Comparing trial designs, patient cohorts and study results
• Anti-IL5 therapies for asthma
• Mepolizumab Prescribing Information
• Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX Study
• Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype
• Prognostic and Predictive Value of Blood Eosinophil Count, Fractional Exhaled Nitric Oxide, and Their Combination in Severe Asthma: A Post Hoc Analysis
• Usability of mepolizumab single-use prefilled syringe for patient self-administration
• International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
• National Jewish Health Inhaler Instructional Videos

Chronic Spontaneous Urticaria (CSU)

• Current and Emerging Therapies for Chronic Spontaneous Urticaria: A Narrative Review
• Chronic spontaneous urticaria: Focus on pathophysiology to unlock treatment advances
• Dupilumab Improves Urticaria Activity And Quality Of Life In Patients With Chronic Spontaneous Urticaria (CSU)
• Dupilumab Significantly Reduces Itch and Hives in Patients With Chronic Spontaneous Urticaria: Results From a Phase 3 Trial (LIBERTY-CSU CUPID Study A)
• Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks
• Urticaria
• Omalizumab Re-Treatment and Step-Up in Patients with Chronic Spontaneous Urticaria: OPTIMA Trial
• Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria Who Remain Symptomatic on H1 Antihistamines: A Randomized, Placebo-Controlled Study
• Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria
• Ligelizumab for Chronic Spontaneous Urticaria
• Dupilumab Efficacy In Patients With Chronic Spontaneous Urticaria By Ige Level: Liberty-CSU Cupid Study A
• Novel biologics for treatment of chronic spontaneous urticaria
• Dupilumab: A Review of Present Indications and Off-Label Uses
• Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial
• Fenebrutinib in H1 antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial
• Benefits and Harms of Omalizumab Treatment in Adolescent and Adult Patients With Chronic Idiopathic (Spontaneous) UrticariaA Meta-analysis of “Real-world” Evidence
• Total IgE as a Marker for Chronic Spontaneous Urticaria
• Chronic Idiopathic Urticaria
• Chronic spontaneous urticaria: Focus on pathophysiology to unlock treatment advances
• The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria
• XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria
• The burden of chronic spontaneous urticaria is substantial: Real-world evidence from ASSURE-CSU
• A Comparison of the United States and International Perspective on Chronic Urticaria Guidelines
• Patient education: Hives (urticaria) (Beyond the Basics)
• Joint Task Force Guidelines: The diagnosis and management of acute and chronic urticaria: 2014 update
• Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy
• Omalizumab in patients with chronic spontaneous urticaria nonresponsive to H1-antihistamine treatment: results of the phase IV open-label SUNRISE study
• Antihistamine-resistant chronic spontaneous urticaria: 1-year data from the AWARE study